Does your loved one struggle with daytime sleepiness? Would you like to learn more about a potential treatment for daytime sleepiness, cognition, and behavior? Join PWSA | USA, FPWR, and Harmony Biosciences Wednesday, February 16th at 3:30 pm ET for a short presentation followed by Q&A to learn more about the Phase 2 study of Pitolisant that will evaluate the safety of Pitolisant and its effectiveness in treating Excessive Daytime Sleepiness (EDS), behavior, learning, attention and memory, and how Pitolisant affects hunger.
Carrie LarsenView posts by Carrie Larsen
Help Rare Disease Research Efforts by Sharing Blood, Urine Samples with PWS-COMBINEDBrain Biorepository
August 16, 2023
Harmony Biosciences Announces Plan to Begin Phase 3 Trial for Pitolisant Following Meeting with FDA
July 20, 2023
Acadia Pharmaceuticals Announces Next Phase for ACP-101 (Intranasal Carbetocin) After Meeting with FDA
June 14, 2023